When do you think RVX will start giving away all these hundreds of millions of dollars?
Are you suggesting Resverlogix shareholder's are getting a good ROI on a $2M savings? I can discount the value of the probable revenue streams for decades and it would still be a highly questionable deal amendment. The inherent conflict of interest is being demonstrated in unabashed fashion here, imo. But if you really think this amendment is a good deal for RVX only shareholders then bring on your math.
Do you think RVX will be a drug company selling RVX-208 and paying royalties to Zenith?
As far as I can tell the royalties are tied to the products, the compounds. So no matter who or what acquires them a royalty WILL be paid to Zenith. I welcome any correction to this understanding. And with this amendment it is not just the select few ApoA-1 qualifying products, its every single compound present and future without qualification, restriction or conditions.
